29069-24-7

29069-24-7 structure

Name: [2-(11,17-dihydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-yl)-2-oxo-ethyl] 4-[4-[bis(2-chloroethyl)amino]phenyl]butanoate
Chemical Name: prednimustine
CAS Number: 29069-24-7
Molecular Formula: C₃₅H₄₅Cl₂NO₆
Molecular Weight: 646.64100
Catalog: API Antineoplastic agents Alkylating agent
Create Date: 2018-07-03 17:03:18
Modify Date: 2024-01-08 20:33:07
Prednimustine (Leo 1031;NSC 134087) is the ester formed from Prednisolone (HY-17463) and Chlorambucil (HY-13593). Prednimustine can be used for leukemias and lymphomas research[1].

Name	prednimustine
Synonyms	precorrin-6y 3,7,12,17-Corrintetrapropanoic acid,2,8,13,18-tetrakis(carboxymethyl)-7,8,11,12-tetradehydro-9,10,11,22-tetrahydro-3,9,13,18,19-pentamethyl-,(1R-(1alpha,2alpha,3beta,9beta,13alpha,17beta,18alpha,19beta))

Description	Prednimustine (Leo 1031;NSC 134087) is the ester formed from Prednisolone (HY-17463) and Chlorambucil (HY-13593). Prednimustine can be used for leukemias and lymphomas research[1].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Cell Cycle/DNA Damage >> DNA Alkylator/Crosslinker
In Vivo	Prednimustine (120 mg/kg; s.c.; single dose) shows much less toxic than equimolar doses of Chlorambucil (HY-13593) (60 mg/kg; s.c.; single dose) in non-tumour-bearing rat model, due to differences in alkylating agent pharmacokinetics[1]. Prednimustine (40 mg/kg; s.c.; single dose) produces low plasma concentrations (less than 5 microM) of the alkylating metabolites chlorambucil and phenyl acetic mustard, which were maintained for 48 h in rats bearing the sensitive strain of the Walker 256 carcinosarcoma grown as an ascites[1]. Prednimustine (40 mg/kg;s.c.; single dose; measured at 72 h) shows antitumor effect in rats model with the alkylating agent-resistant strain of the Yoshida sarcoma[1]. Animal Model: Female Wistar rats non-tumour-bearing (150-200g)[1] Dosage: 120 mg/kg Administration: Subcutaneous injection; single dose; observed at day 21 Result: Remained 100% survival of rats, while 0% survival for Chlorambucil treatment group. Animal Model: Female Wistar rats bearing the alkylating agent-resistant strain of the Yoshida sarcoma (150-200g)[1] Dosage: 40 mg/kg Administration: Subcutaneous injection; single dose Result: Killed 57% of the resistant tumour cells.

CHEMICAL NAME :: Pregna-1,4-diene-3,20-dione, 11-beta,17,21-trihydroxy-, 21-(4-(p-(bis(2-chloroethyl)amino) phenyl)butyrate)

TOXIC EFFECTS :: Behavioral - euphoria Blood - leukopenia Blood - thrombocytopenia

REFERENCE :: JNMDBO Journal of Medicine (Westbury, NY). (PJD Pub., Ltd., POB 966, Westbury, NY 11590) V.1- 1970- Volume(issue)/page/year: 8,115,1977

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: DRFUD4 Drugs of the Future. (J.R. Prous, S.A., Apartado de Correos 540, 08080 Barcelona, Spain) V.1- 1975/76- Volume(issue)/page/year: 1,137,1976

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: EJCAAH European Journal of Cancer. (Oxford, UK) V.1-17(6), 1965-1981. For publisher information, see EJCODS. Volume(issue)/page/year: 13,873,1977

REFERENCE :: EJCAAH European Journal of Cancer. (Oxford, UK) V.1-17(6), 1965-1981. For publisher information, see EJCODS. Volume(issue)/page/year: 13,873,1977 *** REVIEWS *** IARC Cancer Review:Animal Inadequate Evidence IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972- Volume(issue)/page/year: 50,115,1990 IARC Cancer Review:Human No Adequate Data IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972- Volume(issue)/page/year: 50,115,1990 IARC Cancer Review:Group 3 IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972- Volume(issue)/page/year: 50,115,1990